Practical Geriatrics ›› 2026, Vol. 40 ›› Issue (2): 206-210.doi: 10.3969/j.issn.1003-9198.2026.02.020
Previous Articles Next Articles
YAO Zitong, DANG Xiaoyu, FAN Haoling, ZHU Xiangyu, HUANG Jingjing, FENG Ganzhu
Received:2025-07-31
Online:2026-02-20
Published:2026-02-27
Contact:
FENG Ganzhu, Email: fgz62691@163.com
CLC Number:
YAO Zitong, DANG Xiaoyu, FAN Haoling, ZHU Xiangyu, HUANG Jingjing, FENG Ganzhu. Research advances in hematologic impairments combined with respiratory viral infections in the elderly[J]. Practical Geriatrics, 2026, 40(2): 206-210.
| [1] Centers for Disease Control and Prevention. Flu and People 65 Years and Older[EB/OL]. (2025-02-14)[2025-07-22] . https://www.cdc.gov/flu/highrisk/65over.htm. [2] National Institute for Health and Care Excellence. Overview | Pneumonia in adults | Quality standards | NICE[EB/OL]. [2025-07-22] . https://www.nice.org.uk/guidance/QS110. [3] FERNÁNDEZ MAESTRE I, HARRIS A S, AMOR C. Aging and immunity: the age-old tango[J]. Genes Dev, 2025, 39(15/16): 948-974. [4] YU S. Comparison of clinical characteristics and peripheral blood tests of COVID-19 and influenza B patients[J]. Am J Trop Med Hyg, 2023, 108(5): 1028-1030. [5] TIZAZU A M, GIZE A, ALI S. Age influences blood cell-based immune deregulation antibody response and unfavorable clinical outcomes in COVID-19 patients[J]. Sci Rep, 2025, 15(1): 17431. [6] REN Z F, XIONG R C, WANG L L, et al. The well-defined antiphospholipid syndrome induced by COVID-19: a rare case report and review of the literature[J]. Thromb J, 2024, 22(1): 99. [7] PRZYBYLOWICZ P K, KLEPINOWSKI T, TARYMA-LES'NIAK O, et al. Evaluation of methylation changes in blood cells of COVID-19 patients as a biomarker of severity of the infection[J]. BMC Infect Dis, 2025, 25(1): 778. [8] BADULESCU O V, POPESCU D, CIOCOIU M, et al. Immune thrombocytopenia, severe hematological consequence in a patient with COVID-19: a case report[J]. Exp Ther Med, 2021, 22(3): 1043. [9] CHOUDHURY S, DUBEY S, ZUMU M, et al. The role of platelet parameters in predicting the disease severity of COVID-19 patients:a hospital-based study[J]. Cureus, 2024, 16(1): e51523. [10] TSIATSIOU P,TSAIRELI V, MAKRIS M, et al. Transient platelet satellitism and cellular phagocytosis associated with type a influenza virus infection: a case report[J]. Cureus, 2025, 17(3): e79882. [11] KARAPETYAN A, NIAZYAN L, SHUSHANYAN R, et al. Morphological abnormalities of peripheral blood cells among patients with COVID-19 disease[J]. Heliyon, 2024, 10(2): e24527. [12] HAEBERER M, MENGEL M, FAN R, et al. RSV risk profile in hospitalized adults and comparison with influenza and COVID-19 controls in Valladolid, Spain, 2010-2022[J]. Infect Dis Ther, 2024, 13(9): 1983-1999. [13] VERDIER V, LILIENTHAL F, DESVERGEZ A, et al. Severe forms of influenza infections admitted in intensive care units: analysis of mortality factors[J]. Influenza Other Respir Viruses, 2023, 17(7): e13168. [14] VANGETI S, FALCK-JONES S, YU M, et al. Human influenza virus infection elicits distinct patterns of monocyte and dendritic cell mobilization in blood and the nasopharynx[J]. eLife, 2023, 12: e77345. [15] OSYODLO G V, HUSIEVA S A, SVICHAROVA S V, et al. Autoimmune hemolytic anemia associated with COVID-19 infection in a patient with high cardio-metabolic risk[J]. Mil Med, 2024, 189(9/10): e2274-e2279. [16] LEIBRANDT R, ANGELINO K, VIZEL-SCHWARTZ M, et al. Paroxysmal cold hemoglobinuria in an adult with respiratory syncytial virus[J]. Case Rep Hematol, 2018, 2018: 7586719. [17] MAUGERI N, DE LORENZO R, CLEMENTI N, et al. Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19[J]. J Thromb Haemost, 2022, 20(2): 434-448. [18] ZHANG J, HUANG X, DING D, et al. Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases[J]. Exp Hematol Oncol, 2021, 10(1): 34. [19] CERIZ T, LAGARTEIRA J, ALVES S R, et al. Disseminated intravascular coagulation in COVID-19 setting:a clinical case description[J]. Cureus, 2023, 15(6): e39941. [20] CONNORS J M, LEVY J H. COVID-19 and its implications for thrombosis and anticoagulation[J]. Blood, 2020, 135(23): 2033-2040. [21] QURESHI A I, BASKETT W I, HUANG W, et al. Acute ischemic stroke and COVID-19:an analysis of 27676 patients[J]. Stroke, 2021, 52(3): 905-912. [22] BACHLER M, BÖSCH J, STÜRZEL D P, et al. Impaired fibrinolysis in critically ill COVID-19 patients[J]. Br J Anaesth, 2021, 126(3): 590-598. [23] ZHAO Y H, ZHAO L, YANG X C, et al. Cardiovascular complications of SARS-CoV-2 infection (COVID-19):a systematic review and meta-analysis[J]. Rev Cardiovasc Med, 2021, 22(1): 159-165. [24] ZHANG B, GONG J L, ZENG H L, et al. Unveiling fatal risk factors: predicting hemophagocytic lymphohistiocytosis in SFTS patients[J]. PLoS Negl Trop Dis, 2025, 19(6): e0013207. [25] MOLINA G, CONTRERAS R, COOMBES K, et al. Hemophagocytic lymphohistiocytosis following COVID-19 infection[J]. Cureus, 2023, 15(1): e34307. [26] YANG K, XING M Y, JIANG L Y, et al. Infection-associated hemophagocytic syndrome in critically ill patients with COVID-19[J]. Curr Med Sci, 2021, 41(1): 39-45. [27] LAI S, MERRITT B Y, CHEN L, et al. Hemophagocytic lymphohistiocytosis associated with influenza A (H1N1) infection in a patient with chronic lymphocytic leukemia:an autopsy case report and review of the literature[J]. Ann Diagn Pathol, 2012, 16(6): 477-484. [28] TANE M, KOSAKO H, SONOKI T, et al. TAFRO syndrome and COVID-19[J]. Biomedicines, 2024, 12(6): 1287. [29] MILADINOVIC M, KLUSMANN J H. Influenza A (H1N1) virus induced long-term remission in a refractory acute myeloid leukaemia[J]. Br J Haematol, 2023, 202(4): 713-714. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
|